logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

The pharmaceutical industry’s plan to expand clinical trials in primary care

Only 7.5% are carried out in health centres. In order to alleviate this situation, Farmaindustria has presented a programme to promote them in outpatient clinics.

Foto: Foto de archivo de un laboratorio. (EFE/Enric Fontcuberta)

Source: alimente.elconfidencial.com

Spain authorised more than 900 clinical trials with medicines in 2022, according to the Spanish Clinical Trials Register (REEC), which is coordinated by the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios). Despite being close to a thousand, “only 7.5% of clinical trials in Spain involve a primary care specialist”, explained Farmaindustria’s Director of Relations with the Autonomous Communities, José Ramón Luis-Yagüe. In this context, the pharmaceutical industry association has launched a project to promote clinical trials in outpatient clinics. “We have more than 3,000 health centres in which 50,000 healthcare professionals work. Against that we have 832 hospitals. We have to take advantage of this opportunity,” Luis-Yagüe said this week at the 19th Pharmaceutical Industry and Media Seminar.

Specifically, they want a patient with a chronic pathology who is being monitored at their health centre to have the opportunity to participate in a clinical trial on their ailment elsewhere. This project to promote clinical trials in health centres is “an opportunity for the country”, as the plan goes into the need to train professionals in this area, provide the centres with resources to enable research and achieve good coordination with the regional health authorities; all of this by promoting public-private collaboration. “The best example we have in Spain of public-private collaboration is clinical trials, and their management must be streamlined,” said Luis-Yagüe.

For the director general of Farmaindustria, Juan Yermo, “there is an opportunity for research in primary care, which will be an incentive for doctors in this speciality, as these professionals are in great need of motivation”. All the scientific societies representing primary care, foundations and research institutes, the administration of six autonomous communities, nine pharmaceutical companies and three patient organisations, such as the Platform of Patient Organisations, have participated in the development of this plan.

A guide with 8 recommendations

Although it is an “ambitious” project, as Luis-Yagüe himself pointed out, the first step has been to create a guide. The document, currently awaiting publication, reflects the strengths, weaknesses, barriers and opportunities identified to promote clinical research at this level of care and, at the same time, includes a series of strategic recommendations to help the different public and private agents in the field. The guide contains eight recommendations to promote clinical research with medicines in outpatient settings. The first of these is to foster a research culture and to develop a specific regional strategy for clinical research in primary care.

It also aims to facilitate, recognise and encourage clinical research and place technology at its service, as well as to create and promote networks that activate the participation of health centres in clinical research. In addition to promoting public-private collaboration, the plan seeks to harmonise, simplify and streamline the management of clinical research. Finally, it seeks to promote the participation and interest of society in clinical trials at this level of care.

Related entries

13 May, 2025

Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years


Leer más
12 May, 2025

Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.


Leer más
8 May, 2025

Spain, a European success story in clinical trials of new drugs


Leer más

Recent Posts

  • Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years
  • Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.
  • Spain, a European success story in clinical trials of new drugs
  • Joint position on the draft Medicines and Medical Devices Law
  • The global pharmaceutical industry had 12,700 drugs in development by 2024

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.